Diferencia entre revisiones de «Raynaud’s disease»
Sin resumen de edición |
Sin resumen de edición |
||
| (No se muestra una edición intermedia de otro usuario) | |||
| Línea 17: | Línea 17: | ||
==Management== | ==Management== | ||
Improve quality of life and prevent ischemic tissue injury | ''Improve quality of life and prevent ischemic tissue injury'' | ||
*Patient education on trigger avoidance | *Patient education on trigger avoidance | ||
*Severe cases/Ischemia | *Severe cases/Ischemia | ||
| Línea 36: | Línea 36: | ||
==External Links== | ==External Links== | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Vascular]] | |||
Revisión actual - 01:24 16 sep 2018
Background
- Exaggerated vascular response to cold or emotional stress
Clinical Features
- Sharp demarcated color changes of the skin of the digits
- Pain, loss of sensation, and if recurrent ischemia may cause ulcers
Differential Diagnosis
- Primary (Raynaud disease or idiopathic Raynaud Phenomenon)
- Symptoms without an associated disorder
- Secondary (associated with another illness, i.e. SLE or Scleroderma)
Evaluation
- Assess for digital ischemia
- Consider evaluation for underlying disorder
Management
Improve quality of life and prevent ischemic tissue injury
- Patient education on trigger avoidance
- Severe cases/Ischemia
- Pharmacologic
- Oral vasodilators
- Nifedipine 30 to 180 mg/day
- Amlodipine 5 to 20 mg/day
- Topical nitrates
- Phosphodiesterase 5 inhibitors
- Oral vasodilators
- Surgical sympathetic blockade
- Pharmacologic
Disposition
Patient with digital ischemia not responsive to oral or topical vasodilators may need anticoagulants, IV prostanoids, and sympathectomy